ES2073081T3 - Proteinas de fusion a base de interleucina-2 e hirudina. - Google Patents

Proteinas de fusion a base de interleucina-2 e hirudina.

Info

Publication number
ES2073081T3
ES2073081T3 ES91114412T ES91114412T ES2073081T3 ES 2073081 T3 ES2073081 T3 ES 2073081T3 ES 91114412 T ES91114412 T ES 91114412T ES 91114412 T ES91114412 T ES 91114412T ES 2073081 T3 ES2073081 T3 ES 2073081T3
Authority
ES
Spain
Prior art keywords
hirudine
interleukin
fusion proteins
proteins based
interleuquin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91114412T
Other languages
English (en)
Inventor
Paul Dr Habermann
Friedrich Dr Wengenmyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2073081T3 publication Critical patent/ES2073081T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

PROTEINA DE FUSION DE INTERLEUQUIN-2 (IL-2) E HIRUDIN, CUYOS COMPONENTES TIENEN PROPIEDADES BIOLOGICAS, SE OBTIENE A TRAVES DE LA EXPRESION DE LOS CORRESPONDIENTES GENES FUSIONADOS. ADEMAS LA PARTE-IL-2 SE DESARROLLA COMO "PARTE DE LASTRE" QUE SE PROTEGE DE LA DESINTEGRACION A TRAVES DE PROTEASAS.
ES91114412T 1985-11-27 1986-11-21 Proteinas de fusion a base de interleucina-2 e hirudina. Expired - Lifetime ES2073081T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19853541856 DE3541856A1 (de) 1985-11-27 1985-11-27 Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens

Publications (1)

Publication Number Publication Date
ES2073081T3 true ES2073081T3 (es) 1995-08-01

Family

ID=6286938

Family Applications (3)

Application Number Title Priority Date Filing Date
ES198686116140T Expired - Lifetime ES2032378T3 (es) 1985-11-27 1986-11-21 Procedimiento para preparar una proteina de fusion.
ES91114411T Expired - Lifetime ES2077747T3 (es) 1985-11-27 1986-11-21 Derivados de hirudina.
ES91114412T Expired - Lifetime ES2073081T3 (es) 1985-11-27 1986-11-21 Proteinas de fusion a base de interleucina-2 e hirudina.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES198686116140T Expired - Lifetime ES2032378T3 (es) 1985-11-27 1986-11-21 Procedimiento para preparar una proteina de fusion.
ES91114411T Expired - Lifetime ES2077747T3 (es) 1985-11-27 1986-11-21 Derivados de hirudina.

Country Status (17)

Country Link
EP (3) EP0227938B1 (es)
JP (1) JP2566933B2 (es)
KR (1) KR950000300B1 (es)
AT (2) ATE127841T1 (es)
AU (1) AU595262B2 (es)
CA (1) CA1341203C (es)
DE (4) DE3541856A1 (es)
DK (2) DK172064B1 (es)
ES (3) ES2032378T3 (es)
FI (1) FI93471C (es)
GR (1) GR3005042T3 (es)
HU (1) HU203579B (es)
IE (1) IE59488B1 (es)
IL (1) IL80755A0 (es)
NO (1) NO176481C (es)
PT (1) PT83813B (es)
ZA (1) ZA868943B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3125021A (en) * 1955-11-14 1964-03-17 Smooth
DE3583361D1 (de) * 1984-06-14 1991-08-08 Ucp Gen Pharma Ag Verfahren zur herstellung von thrombin-inhibitoren.
DE3712985A1 (de) * 1987-04-16 1988-11-03 Hoechst Ag Bifunktionelle proteine
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
DE3819079A1 (de) * 1988-06-04 1989-12-07 Hoechst Ag Hirudin-derivate mit verzoegerter wirkung
DE3835815A1 (de) * 1988-10-21 1990-04-26 Hoechst Ag Neue isohirudine
DE3844211A1 (de) * 1988-12-29 1990-07-05 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5179196A (en) * 1989-05-04 1993-01-12 Sri International Purification of proteins employing ctap-iii fusions
WO1991000912A1 (en) * 1989-07-07 1991-01-24 Massachusetts Institute Of Technology Production and use of hybrid protease inhibitors
CU22222A1 (es) * 1989-08-03 1995-01-31 Cigb Procedimiento para la expresion de proteinas heterologicas producidas de forma fusionada en escherichia coli, su uso, vectores de expresion y cepas recombinantes
GB8927722D0 (en) * 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
DE3942580A1 (de) * 1989-12-22 1991-06-27 Basf Ag Verfahren zur herstellung von hirudin
US5270181A (en) * 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
DE4140381A1 (de) * 1991-12-07 1993-06-09 Hoechst Ag, 6230 Frankfurt, De Neue synthetische isohirudine mit verbesserter stabilitaet
DE4404168A1 (de) * 1994-02-10 1995-08-17 Hoechst Ag Hirudinderivate und Verfahren zu deren Herstellung
PT821006E (pt) 1996-07-26 2004-09-30 Aventis Pharma Gmbh Derivados de insulina com ligacao a zinco aumentada
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
DE19825447A1 (de) 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
DE10033195A1 (de) * 2000-07-07 2002-03-21 Aventis Pharma Gmbh Bifunktionale Fusionsproteine aus Hirudin und TAP
US7202059B2 (en) 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium
US7638618B2 (en) 2001-02-20 2009-12-29 Sanofi-Aventis Deutschland Gmbh Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
PH12011502708B1 (en) 2009-07-06 2017-11-10 Sanofi Aventis Deutschland Insulin preparations containing methionine
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
JP5832439B2 (ja) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Glp−1アゴニスト、インスリン及びメチオニンを含む薬学的組成物
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 2型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
KR20200080747A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
KR20200080748A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
DK108685A (da) * 1984-03-19 1985-09-20 Fujisawa Pharmaceutical Co Vaekstfaktor i
DE3586333T2 (de) * 1984-03-27 1992-12-10 Transgene Sa Expressionsvektoren fuer hirudin, transformierte zellen und verfahren zur herstellung von hirudin.
EP0158198A1 (en) * 1984-03-29 1985-10-16 Takeda Chemical Industries, Ltd. DNA and use thereof
DE3429430A1 (de) * 1984-08-10 1986-02-20 Hoechst Ag, 6230 Frankfurt Gentechnologisches verfahren zur herstellung von hirudin und mittel zur durchfuehrung dieses verfahrens
DE3526995A1 (de) * 1985-07-27 1987-02-05 Hoechst Ag Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung
US4865974A (en) * 1985-09-20 1989-09-12 Cetus Corporation Bacterial methionine N-terminal peptidase
CA1297003C (en) * 1985-09-20 1992-03-10 Jack H. Nunberg Composition and method for treating animals

Also Published As

Publication number Publication date
ES2032378T3 (es) 1993-02-16
FI864798A0 (fi) 1986-11-25
FI93471C (fi) 1995-04-10
NO176481B (no) 1995-01-02
FI93471B (fi) 1994-12-30
PT83813B (pt) 1989-06-30
DE3541856A1 (de) 1987-06-04
JPS62143696A (ja) 1987-06-26
DE3650396D1 (de) 1995-10-19
DE3684892D1 (de) 1992-05-21
DK568586D0 (da) 1986-11-26
EP0227938A2 (de) 1987-07-08
PT83813A (de) 1986-12-01
EP0227938B1 (de) 1992-04-15
HU203579B (en) 1991-08-28
DK568586A (da) 1987-05-28
EP0227938A3 (en) 1988-11-23
ATE127841T1 (de) 1995-09-15
KR870005098A (ko) 1987-06-04
ZA868943B (en) 1987-07-29
FI864798L (fi) 1987-05-28
KR950000300B1 (ko) 1995-01-13
ATE122397T1 (de) 1995-05-15
ES2077747T3 (es) 1995-12-01
CA1341203C (en) 2001-03-13
EP0464867A1 (de) 1992-01-08
DK52292D0 (da) 1992-04-21
EP0468539B1 (de) 1995-09-13
JP2566933B2 (ja) 1996-12-25
EP0468539A1 (de) 1992-01-29
GR3005042T3 (es) 1993-05-24
DK52292A (da) 1992-04-21
NO176481C (no) 1995-04-12
DE3650322D1 (de) 1995-06-14
DK172210B1 (da) 1998-01-05
AU595262B2 (en) 1990-03-29
HUT43642A (en) 1987-11-30
IE863119L (en) 1987-05-27
NO864759D0 (no) 1986-11-26
EP0464867B1 (de) 1995-05-10
AU6569386A (en) 1987-06-04
DK172064B1 (da) 1997-10-06
IE59488B1 (en) 1994-03-09
IL80755A0 (en) 1987-02-27

Similar Documents

Publication Publication Date Title
FI831228A0 (fi) Framstaellning av funktionellt maenskligt urokinasprotein
FI920764A0 (fi) Fusionsproteiner omfattande gm-csf och il-3.
ATE339507T1 (de) Erythropoietin-analog-menschliches serum-albumin fusionsprotein
DE68927088D1 (de) Menschlicher Gefässpermeabilitätsfaktor
NO833793L (no) Cystein-manglende muteiner av biologisk aktive proteiner
ES2077747T3 (es) Derivados de hirudina.
DE3586313D1 (de) Konjugate von pharmazeutisch nuetzlichen proteinen.
IS5887A (is) Interferón-beta bræðsluprótín og notkun þeirra
NO864569D0 (no) Modifiserte fibrinolyttiske midler.
FI904851A0 (fi) Radiomaerkta antikoagulantpeptider.
FI854383A0 (fi) Foerfarande foer avspaltning av peptider och proteiner av metionyl-bindning.
ATE82857T1 (de) Interleukin-2-zusammensetzungen.
ATE41773T1 (de) 4,5-dihydro-4-oxo-2((2-transphenylcyclopropyl)amino>-3-furancarbonsaeuren und derivate davon.
ES2084658T3 (es) Genes codificantes de una proteina con actividad macif humana, vectores de expresion que contienen los indicados genes, celulas transformadoras y proteinas con actividad macif humana.
DK226889A (da) Alkoholpeptidderivat samt anvendelse deraf til mindskning af blodkoagulation
ES2074591T3 (es) Expresion de polipeptidos de vih 1 y 2 y su utilizacion.
FI882741A7 (fi) Rekombinantti-HTLV-III-proteiineja ja niiden käyttötapoja.
NO894573D0 (no) Rekombinante interleukin-2 hybridproteiner.
ES2056872T3 (es) Proteina pp4-x anticoagulante, su preparacion y empleo.
ES2078908T3 (es) Un procedimiento para la formacion de un puente intramolecular de disulfuro en un polipeptido.
ES2162801T3 (es) Factor que regula la expresion genica.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 464867

Country of ref document: ES